Award
National Cancer Institute 5R01CA275967-04
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
Recipient
State University of New York at Buffalo
Award Amount
$428,904.00
Ceiling
$428,904.00
Awarded
January 14, 2026
Identifier
5R01CA275967-04
NIH/NCI awarded a project to optimize ADC therapy for AML using pharmacokinetic/pharmacodynamic modeling and antibody development.
Description
This project focuses on developing new strategies to improve the safety and efficacy of antibody-drug conjugate (ADC) therapy for acute myeloid leukemia (AML). It involves mechanistic pharmacokinetic/pharmacodynamic modeling, development of monoclonal antibodies and nanobodies, bispecific constructs, and in vivo experiments in mouse models. The project is funded by the NIH/NCI under award number 5R01CA275967-04.